Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.
Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease.
复制标题
眼眶和背外侧额叶灌注缺陷与阿尔茨海默病胆碱酯酶抑制剂治疗的行为反应相关。
DOI：
10.1176/jnp.12.2.209
复制
发表时间：
2000
期刊：
影响因子：
--
通讯作者：
Cummings,JL
中科院分区：
文献类型：
--
作者：
Mega,MS;Dinov,ID;Lee,L;O'Connor,SM;Masterman,DM;Wilen,B;Mishkin,F;Toga,AW;Cummings,JL
作者采用神经精神量表（NPI）和基线[99mTc]HMPAO SPECT回顾性研究了对胆碱酯酶抑制剂治疗有反应的阿尔茨海默病（AD）患者的行为和功能成像特征。30例AD患者根据他们对多奈哌齐的行为反应分为三组（反应者，无反应者和不变者）。与无应答者相比，应答者治疗前的易激惹、抑制解除（P≤0.05）和欣快（P=0.05）显著（P≤0.01），双侧眶额外侧（P<0.00001）和背外侧额叶（P≤0.0005）灌注显著降低。治疗前眶额综合征可预测AD患者对胆碱酯酶抑制剂治疗的行为反应。
The authors retrospectively explored the behavioral and functional imaging profile of Alzheimer's disease (AD) patients who respond to cholinesterase inhibitor therapy by using the Neuropsychiatric Inventory (NPI) and baseline [99mTc]HMPAO SPECT. Thirty AD patients were divided into three groups (Responders, Nonresponders, and Unchanged) based on their behavioral response to donepezil. Responders had significantly (P≤0.01) more pretreatment irritability, disinhibition (P≤0.05), and euphoria (P=0.05) than Nonresponders and significantly lower lateral orbital frontal (P<0.00001) and dorsolateral frontal (P≤0.0005) perfusion bilaterally. A pretreatment orbitofrontal syndrome may predict behavioral response to cholinesterase inhibitor therapy in AD.